Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Michelle Pfeiffer has apologized after parroting a fringe theory that a food product with ties to Bill Gates would ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...

President Donald Trump teased the announcement last week, but Coca-Cola finally confirmed it Tuesday: a version of Coke’s ...

Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

In fact, the recent 2022 update to the FDA’s Food Code calls ... require measures like allergen notice posters in kitchens, ...